6-氟-4-肼基-2-甲基喹啉 | 49612-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氟-4-肼基-2-甲基喹啉
• 英文名称: 1-(6-fluoro-2-methylquinolin-4-yl)hydrazine
• 英文别名: (6-Fluoro-2-methylquinolin-4-yl)hydrazine
• CAS: 49612-15-9
• 化学式: C₁₀H₁₀FN₃
• 分子量: 191.208
• InChiKey: AWERKEQRUWLUJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-氟-4-肼基-2-甲基喹啉 在 盐酸 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 2-(6-Fluoro-2-methylquinolin-4-yl)-4,5,6,7-tetrahydroindazol-5-amine
  参考文献：
  名称：

  Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains

  摘要：

  We have previously reported a novel class of tetrahydroindazoles that display potency against a variety of Gram-positive and Gram-negative bacteria, potentially via interaction with type II bacterial topoisomerases. Herein are reported SAR investigations of this new series. Several compounds possessing broad-spectrum potency were prepared. Further, these compounds exhibit activity against multidrug-resistant Gram-positive microorganisms equivalent to that against susceptible strains. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.004
• 作为产物：
  描述：

  6-氟-4-氢-2-甲基喹啉 在 一水合肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 6-氟-4-肼基-2-甲基喹啉
  参考文献：
  名称：

  某些含氟活性喹啉-吡唑杂化衍生物的合成及其抗结核和抗菌活性

  摘要：

  为了开发出新的抗结核和抗菌药物以抵抗不断增加的细菌耐药性，我们采用分子杂交方法设计了新的喹啉-吡唑类似物（8a – u）。通过单晶X射线衍射（SC-XRD）分析清楚地证实了最终化合物之一8a的结构。评价目标化合物对结核分枝杆菌的抗结核活性和对三种常见致病细菌菌株的抗菌活性。四个导数（8b，8c，8j和8o）具有明显的抗结核活性。衍生自在吡唑环上具有卤素取代基的8-三氟甲基喹啉和6-氟喹啉骨架的化合物表现出比相应的6-甲氧基喹啉类似物更好的抑制活性。细胞毒性研究表明，活性化合物对正常Vero细胞系无毒，选择性指数值≥10，表明这些化合物适用于进一步的药物开发。的在计算机芯片上的分子对接研究表明用的靶酶（INHA，CYP121和TMPK）化合物的强的结合亲和力的结核分枝杆菌。此外，化合物8b，8c，8d和8g的体外抗菌活性 与参考药物环丙沙星相当。

  DOI：

  10.1016/j.jfluchem.2016.01.011

文献信息

• Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives
  作者：Sandra Gemma、Gagan Kukreja、Pierangela Tripaldi、Maria Altarelli、Matteo Bernetti、Silvia Franceschini、Luisa Savini、Giuseppe Campiani、Caterina Fattorusso、Stefania Butini

  DOI：10.1016/j.tetlet.2008.01.128

  日期：2008.3

  Nickel(II) chloride/sodium borohydride combination was employed for the reduction of 4-hydrazinoquinoline derivatives to the corresponding anilines. This reductive protocol was efficiently applied for the reductive cleavage of monosubstituted hydrazines. We described herein the microwave-assisted synthesis of 4-hydrazinoquinolines, which furnished a high yielding and rapid two-step procedure for the

  氯化镍（II）/硼氢化钠组合用于将4-肼基喹啉衍生物还原为相应的苯胺。该还原方案被有效地应用于单取代肼的还原裂解。我们在本文中描述了4-肼基喹啉的微波辅助合成，其提供了高产率和快速的两步法，用于在温和条件下合成4-氨基喹啉作为抗疟原体。
• [EN] PYRIDAZINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZINONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010063610A1

  公开（公告）日：2010-06-10

  The present invention is concerned with novel pyridazinone derivatives of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及一种新颖的吡啶并嗪酮衍生物，其化学式为（I），其中R1、R2、R3和R4如描述和权利要求中所定义，并且其生理上可接受的盐和酯。这些化合物抑制PDE10A，可用作药物。
• Pyridazinones
  申请人：Hoffmann-La Roche Inc.

  公开号：US08178538B2

  公开（公告）日：2012-05-15

  The present invention is concerned with novel pyridazinones of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of CNS disorders.

  本发明涉及式（I）的新型吡啶二酮，其中R1、R2、R3和R4在说明书和权利要求中定义，以及其生理上可接受的盐和酯。这些化合物抑制PDE10A，可用于治疗中枢神经系统疾病。
• PYRIDAZINONES
  申请人：Alberati Daniela

  公开号：US20100152193A1

  公开（公告）日：2010-06-17

  The present invention is concerned with novel pyridazinones of formula (I) wherein R 1 , R 2 , R 3 and R 4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of CNS disorders.

  本发明涉及式（I）的新型吡啶二酮化合物，其中R1、R2、R3和R4如所述和所述权利要求中定义，以及其生理上可接受的盐和酯。这些化合物抑制PDE10A，并可用于治疗中枢神经系统疾病。
• N 1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors
  作者：Wei Luo、Wei-Qiang Lu、Kun-Qiang Cui、Yang Liu、Jian Wang、Chun Guo

  DOI：10.1007/s00044-011-9854-3

  日期：2012.10

  A series of N (1)-4-[(10S)-dihydroartemisinin-10-oxyl]}phenylmethylene-N (2)-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain-2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, H-1 NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 mu M). The best one of this series was compound 9d (IC50 = 0.15 mu M). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.